Limited coverage drugs – tocilizumab (for giant cell arteritis)
Last updated on February 21, 2025
|
Generic name |
tocilizumab |
|---|---|
|
Strength |
162 mg/0.9 mL |
|
Form |
pre-filled syringe |
|
Special Authority criteria |
Approval period |
|---|---|
|
For the treatment of giant cell arteritis (GCA), according to criteria detailed in Special Authority Request form HLTH 5496, when a Special Authority request is submitted by a rheumatologist or ophthalmologist. |
1 year |
Practitioner exemptions
- None
Special notes
- None